Published on | 11 months ago
Programmes Digital, Industry & Space AI ContinentOn 1 August 2024, the EU AI Act entered into force. The AI Act is the first-ever legal framework on AI which addresses the risks of AI and provides AI developers and deployers with clear requirements and obligations to ensure that AI developed and used in the EU is trustworthy, to safeguard people's fundamental rights.
The AI Act introduces risk-based approach to define AI systems:
The AI Act also introduces rules for so-called general-purpose AI models, which are highly capable AI models that are designed to perform a wide variety of tasks like generating human-like text.
The AI Act is part of a wider package of policy measures to support the development of trustworthy AI, which also includes the AI Innovation Package. Initiatives under this package include the following:
For applicants planning to submit AI-related project proposals, it is strongly recommended to be aware of relevant legislation and initiatives on EU level and to demonstrate links between their project proposals and these initiatives.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.